# Howard A. Burris

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/howard-a-burris/

## Facts

| Field | Value |
| --- | --- |
| Citations | 72,966 |
| Field | Cancer Treatment and Pharmacology |
| h-index | 118 |
| i10-index | 544 |
| Last Known Institution | Sarah Cannon |
| OpenAlex ID | https://openalex.org/A5072308451 |
| ORCID iD | https://orcid.org/0000-0002-1501-2931 |
| Works | 1,154 |

## Researcher papers

- [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/)
- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/effect-of-interleukin-1-inhibition-with-canakinumab-on-incident-lung-cancer-in/)
- [Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas](https://scholariq.org/papers/phase-i-safety-pharmacokinetics-and-clinical-activity-study-of-lapatinib/)
- [Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study](https://scholariq.org/papers/rovalpituzumab-tesirine-a-dll3-targeted-antibody-drug-conjugate-in-recurrent/)
- [Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial](https://scholariq.org/papers/safety-pharmacokinetic-pharmacodynamic-and-efficacy-data-for-the-oral-mek/)
- [Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial](https://scholariq.org/papers/activity-of-the-oral-mek-inhibitor-trametinib-in-patients-with-advanced-melanoma/)
- [Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study](https://scholariq.org/papers/evaluation-of-bgj398-a-fibroblast-growth-factor-receptor-1-3-kinase-inhibitor-in/)
- [Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial](https://scholariq.org/papers/vorasidenib-a-dual-inhibitor-of-mutant-idh1-2-in-recurrent-or-progressive-glioma/)
- [A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors](https://scholariq.org/papers/a-phase-i-ii-study-of-the-oral-parp-inhibitor-rucaparib-in-patients-with/)

## Researcher topics

- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Researcher university

- [Sarah Cannon](https://scholariq.org/institutions/sarah-cannon/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.